Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study

Marie Viala(Institut de Recherche en Cancérologie de Montpellier), William Jacot(Inserm), Laure Delmond(Institut de Recherche en Cancérologie de Montpellier), Akiko Chiba(Wake Forest University), Sarah L. Mott(University of Iowa), Mary C. Schroeder(University of Iowa), Pierre‐Jean Lamy(Montpellier GenomiX), Simon Thézenas(Institut de Recherche en Cancérologie de Montpellier), Alexandra Thomas(Cliniques Universitaires Saint-Luc)
BMC Cancer
July 30, 2018
10.1186/s12885-018-4686-x
Cited by 28

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
|Cancer Cell|2021|330
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298